THERAPEUTIC DRUG MONITORING OF
CYCLOSPORINE IN TRANSPLANTED PATIENTS.
POSSIBILITIES, CONTROVERSY, CAUSES FOR
FAILURE
CAMIL-EUGEN VARI, AMELIA TERO-VESCAN*, SILVIA IMRE,
DANIELA LUCIA MUNTEAN
Faculty of Pharmacy, University of Mecine and Pharmac Târgu-Mureş
*corresponding autor: terovescan@yahoo.com
DownloadDownload Full Article

Abstract:

Monitoring cyclosporine therapy is required by the narrow therapeutic index, high pharmacokinetic variability, the increased risk of drug interactions CYP 3A4- dependent and nephrotoxicity of the substance substance. The controversies raised by clinical practice are the best time of sampling, the analytical methods used and the feasibility of the pharmacokinetic models to estimate the useful concentrations for
preventing rejection and nephrotoxicity, and inherent pharmacokinetic drug interactions with concomitant treatments.




Top